1 / 34

Gastrointestinal Stromal Tumor GIST: An Update

Outline. Introduction/Clinical featuresPathology featuresMolecular pathogenesisMutation detectionTherapeutic consideration. Introduction. GIST as described in the early literature consisted of a heterogeneous group of mesenchymal tumors, primarily involving the wall of the bowel. The lack of o

hila
Download Presentation

Gastrointestinal Stromal Tumor GIST: An Update

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. Gastrointestinal Stromal Tumor (GIST): An Update Keni Gu, MD, PhD October 5th, 2006

    2. Outline Introduction/Clinical features Pathology features Molecular pathogenesis Mutation detection Therapeutic consideration

    3. Introduction GIST as described in the early literature consisted of a heterogeneous group of mesenchymal tumors, primarily involving the wall of the bowel. The lack of objective criteria encouraged the inclusion of virtually any mesenchymal lesion of the gastrointestinal tract under the rubric of GIST, including desmoid fibromatosis, Schwannoma and leiomyosarcoma, among others. This situation persisted until 1998.

    4. The KIT revolution Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human GIST After the initial findings by Hirota and colleagues in 1998, there has been a virtual explosion of data regarding GIST.

    5. The KIT revolution c-KIT (CD117), a type III receptor tyrosine kinase (RTK) that is involved in the development and maintenance of RBC, mast cells, melanocytes, germ cells and interstitial cells of Cajal (ICC). Loss of function KIT mutations result in anemia, loss of mast cells, white coat spotting due to failure of migration of dermal melanocytes, sterility due to a block in gametogenesis and gastrointestinal abnormalities due to loss of ICC.

    6. GIST GIST, the specific KIT- or platelet-derived growth factor receptor-alpha (PDGFRA)-signaling driven mesenchymal tumor, arising from interstitial cells of Cajal (ICC), or stem cells. Clinicopathological features

    7. 45006000 new cases in the USA alone each year. A wide age range, from pediatric to elderly patients, 75% of GISTs over the age of 50.

More Related